These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
7. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. Gorczyca-Michta I; Wożakowska-Kapłon B Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482 [TBL] [Abstract][Full Text] [Related]
8. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study. Hohnloser SH; Basic E; Nabauer M Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220 [TBL] [Abstract][Full Text] [Related]
15. Bleeding complications with oral anticoagulants in the elderly: an observational study. Peeterbroeck J; Danguy C; Lelubre C; Meulemans M; Higuet S Geriatr Psychol Neuropsychiatr Vieil; 2016 Dec; 14(4):406-412. PubMed ID: 27507064 [TBL] [Abstract][Full Text] [Related]
16. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420 [TBL] [Abstract][Full Text] [Related]
17. A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture. Fiordellisi W; White K; Schweizer M J Gen Intern Med; 2019 Feb; 34(2):304-311. PubMed ID: 30511289 [TBL] [Abstract][Full Text] [Related]
18. Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial). Vossen LM; Schurgers LJ; van Varik BJ; Kietselaer BL; Vermeer C; Meeder JG; Rahel BM; van Cauteren YJ; Hoffland GA; Rennenberg RJ; Reesink KD; de Leeuw PW; Kroon AA Nutrients; 2015 Oct; 7(11):8905-15. PubMed ID: 26516910 [TBL] [Abstract][Full Text] [Related]
19. [Vascular calcifications, the hidden side effects of vitamin K antagonists]. Bennis Y; Vengadessane S; Bodeau S; Gras V; Bricca G; Kamel S; Liabeuf S Therapie; 2016 Sep; 71(4):355-63. PubMed ID: 27203170 [TBL] [Abstract][Full Text] [Related]
20. Intracranial calcifications under vitamin K antagonists or direct oral anticoagulants: Results from the French VIKING study in older adults. Annweiler G; Labriffe M; Ménager P; Ferland G; Brangier A; Annweiler C; Maturitas; 2020 Feb; 132():35-39. PubMed ID: 31883661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]